Initial Dose Adjustment of Zolbetuximab Plus Chemotherapy in CLDN18.2-Positive Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer (GENTLE-Z), a Randomized, Phase II Trial
- 1 November 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Advances
- No. 2
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab + chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.Journal of Clinical Oncology, 2024
- Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trialNature Medicine, 2023
- Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trialThe Lancet, 2023
- Association of CLDN18 Protein Expression with Clinicopathological Features and Prognosis in Advanced Gastric and Gastroesophageal Junction AdenocarcinomasJournal of Personalized Medicine, 2021
- Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinomaJapanese Journal of Clinical Oncology, 2019
- A phase I dose-escalation study of IMAB362 (Zolbetuximab) in patients with advanced gastric and gastro-oesophageal junction cancerEuropean Journal of Cancer, 2018
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody DevelopmentClinical Cancer Research, 2008
- claudin-18 , a Novel Downstream Target Gene for the T/EBP/NKX2.1 Homeodomain Transcription Factor, Encodes Lung- and Stomach-Specific Isoforms through Alternative SplicingMolecular and Cellular Biology, 2001